AzTrials
AzTrials

Supranuclear Palsy, ProgressivePhase 2PASSPORTNCT03068468

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

A Phase 2 study testing BIIB092 in people with Supranuclear Palsy, Progressive, run by Biogen at 86 sites in 13 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to… Read more about this study

Who is it for?
Ages 41 to 86 years
Conditions the study is for
Supranuclear Palsy, Progressive
What is being tested?
BIIB092
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
490 participants
Where
86 sitesin 13 countries
Study dates
1 Jun 2017to 7 Feb 2020
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 41 to 86 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants with probable or possible PSP
  • Able to ambulate independently or with assistance
  • Able to tolerate MRI
  • Have reliable caregiver to accompany participant to all study visits
  • Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening
  • Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned

Who cannot join

  • Presence of other significant neurological or psychiatric disorders
  • Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease
  • History of early, prominent rapid eye movement (REM) sleep behavior disorder
  • History of or screening brain MRI scan indicative of significant abnormality
  • Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Trial locations and contacts

86 sites in 13 countries.

86 sites in 13 countries

United States33 sites
  • Research Site

    Albany, New York, 12208

  • Research Site

    Baltimore, Maryland, 21201

  • Research Site

    Baltimore, Maryland, 21287

  • Research Site

    Boca Raton, Florida, 33486

  • Research Site

    Boston, Massachusetts, 02114

  • Research Site

    Burlington, Massachusetts, 01702

  • Research Site

    Charleston, South Carolina, 29425

  • Research Site

    Charlottesville, Virginia, 22908-0394

  • Research Site

    Chicago, Illinois, 60611

  • Research Name

    Chicago, Illinois, 60612-3841

  • Research Site

    Chicago, Illinois, 60637-1447

  • Research Site

    Dallas, Texas, 75390-8869

  • Research Site

    Farmington Hills, Michigan, 48334

  • Research Site

    Fountain Valley, California, 92708

  • Research Site

    Gainesville, Florida, 32607

  • Research Site

    Hershey, Pennsylvania, 17033

  • Research Site

    Indianapolis, Indiana, 46202-2280

  • Research Site

    Kansas City, Kansas, 66160

  • Research Site

    La Jolla, California, 92037

  • Research Site

    Los Angeles, California, 90095

  • Research Site

    Minneapolis, Minnesota, 55455-0341

  • Research Site

    New Brunswick, New Jersey, 08901

  • Research Site

    New Orleans, Louisiana, 70121-2429

  • Research Site

    New York, New York, 100029

  • Research Site

    New York, New York, 10029

  • Research Site

    New York, New York, 10032-3725

  • Research Site

    Philadelphia, Pennsylvania, 19104

  • Research Site

    Phoenix, Arizona, 85013

  • Research Site

    San Francisco, California, 94158

  • Research Site

    Scottsdale, Arizona, 85259

  • Research Site

    Seattle, Washington, 98122

  • Research Site

    Sun City, Arizona, 85351

  • Research Site

    Tampa, Florida, 33612-4742

Other trials in United States

Germany13 sites
  • Research Site

    Beelitz-Heilstätten

  • Research Site

    Bochum

  • Research Site

    Bonn

  • Research Site

    Dresden, Saxony

  • Research Site

    Düsseldorf, North Rhine-Westphalia

  • Research Site

    Essen

  • Research Site

    Kassel

  • Research Site

    Kiel, Schleswig-Holstein

  • Research Site

    Lübeck, Schleswig-Holstein

  • Research Site

    Marburg, Hesse

  • Research Site

    Munich, Bavaria

  • Research Site

    Rostock, Mecklenburg-Western-Pommerania

  • Research Site

    Ulm

Other trials in Germany

France7 sites
  • Research Site

    Bordeaux

  • Research Site

    Lille

  • Research Site

    Marseille

  • Research Site

    Nîmes

  • Research Site

    Paris

  • Research Site

    Rennes

  • Research Site

    Toulouse

Other trials in France

Japan7 sites
  • Research Site

    Kamagaya, Chiba

  • Research Site

    Kodaira, Tokyo

  • Research Site

    Nagoya, Aichi-ken

  • Research Site

    Sagamihara, Kanagawa

  • Research Site

    Sapporo, Hokkaido

  • Research Site

    Shizuoka

  • Research Site

    Yonago, Tottori

Other trials in Japan

United Kingdom7 sites
  • Research Site

    Brighton, East Sussex

  • Research Site

    Cambridge, Cambridgeshire

  • Research Site

    Liverpool, Merseyside

  • Research Site

    London

  • Research Site

    Newcastle upon Tyne, Tyne and Wear

  • Research Site

    Newport, Wales

  • Research Site

    Southampton, Hampshire

Other trials in United Kingdom

Spain6 sites
  • Research Site

    Barakaldo, Vizcaya

  • Research Site

    Barcelona

  • Research Site

    Madrid

  • Research Site

    Pamplona, Navarre

  • Research Site

    Seville

  • Research Site

    Valencia

Other trials in Spain

Canada3 sites
  • Research Site

    London, Ontario

  • Research Site

    Ottawa, Ontario

  • Research Site

    Toronto, Ontario

Other trials in Canada

Italy3 sites
  • Research Site

    Pisa

  • Research Site

    Salerno, Campania

  • Research Site

    Venice-Lido

Other trials in Italy

Austria2 sites
  • Research Site

    Innsbruck, Tyrol

  • Research Site

    Vienna

Other trials in Austria

Russia2 sites
  • Research Site

    Krasnoyarsk

  • Research Site

    Moscow

Other trials in Russia

Australia1 site
  • Research Site

    North Melbourne, Victoria

Other trials in Australia

Greece1 site
  • Research Site

    Athens, Marousi

Other trials in Greece

South Korea1 site
  • Research Site

    Seoul

Other trials in South Korea

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 \& 4 laboratory abnormalities.

The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by the Clinical Global Impression of Change (CGI-C) at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) at Week 52 and to assess the impact of BIIB092 on quality of life, relative to placebo, as measured by change from baseline on the Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) at Week 52.

Read the detailed description

This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.

Being tested
BIIB092, Placebo
Medical subject headings
Supranuclear Palsy, Progressive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BIIB092Drug

    Also called BMS-986168

    BIIB092 intravenous infusion on specified days

  • PlaceboDrug

    Placebo intravenous infusion on specified days

Study groups in NCT03068468
Study groupRoleWhat they receive
BIIB092ExperimentalParticipants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
Receives: Drug: BIIB092
PlaceboPlacebo comparatorParticipants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52

    The PSPRS is a quantitative measure of disability in participants with PSP. The PSPRS comprises 28 items in 6 areas. Six items are rated on a 3-point scale (0-2) and 22 are rated on a 5-point scale (0-4). The 6 areas are the History/Daily Activities, Mentation, Bulbar, Ocular Motor, Limb Motor, and Gait. The 28-item PSPRS total score ranges from 0 (normal) to 100. Fifteen items are selected to form a 15-item PSPRS and three domains are identified: Gait/Limb function, Ocular Motor, and Bulbar. The total 15-item PSPRS score ranges from 0 (normal) to 52. A positive change from baseline indicates worsening.

    Measured: Baseline, Week 52

  2. Percentage of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug

    AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity.

    Measured: up to 52 weeks

Secondary outcomes (13)
  1. Change From Baseline in Movement Disorder Society (MDS)-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52

    The MDS-UPRDRS Part 2 includes 13 items assessing motor aspects of experiences of daily living (M-EDL) these include speech, saliva and drooling, chewing and swallowing, handwriting, doing hobbies and other activities, eating tasks, tremor, dressing, hygiene, turning in bed, getting out of bed, walking and balance, and freezing. All items have 5 responses with uniform anchors of 0= normal, 1= slight, 2= mild, 3= moderate, and 4= severe. Total score ranges from 0 to 52, higher score indicating severe conditions. A positive change from baseline indicates worsening.

    Measured: Baseline, Week 52

  2. Clinical Global Impression of Change (CGI-C) Scale Score

    The CGI-C scale measures the change in the patient's clinical status from a specific point in time. Using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change.

    Measured: Week 52

  3. Change From Baseline in Progressive Supranuclear Palsy (PSP)-Cognitive Composite Battery Z-Score at Week 52

    The PSP cognitive composite battery is used to identify and characterize abnormal cognitive decline in PSP participants. The PSP cognitive composite battery includes 13 sub-tests in total: 11 tests from the RBANS (only the picture naming is excluded), letter number sequencing test, and phonemic fluency test. Three domains are identified: Memory and learning, Visual-Motor function, and Working memory and Executive. A z-score transformation is applied for each component test at each visit, and the final total composite z-score is the average of the three-domain z-scores. A z-score of 0 is equal to the estimated mean adjusted by age and is considered average for this study population. Lower values are indicative of cognitive decline. A negative change from baseline indicates worsening.

    Measured: Baseline, Week 52

  4. Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52

    The RBANS provides both a total scale score and scores for 5 different cognitive domains. Specifically, the test measures immediate memory, visuospatial/constructional ability, language, attention, and delayed memory. Scores from all subtests are aggregated into a total composite score. RBANS data were age-normed and analyzed as index scores (also referred to as standard scores), which have a mean of 100 and a standard deviation of 15. Higher scores on each sub measure and index indicate better performance. A negative change from baseline indicates worsening.

    Measured: Baseline, Week 52

  5. Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score

    The PSP-QoL is a patient-reported outcome measure developed specifically for assessing the health-related quality of life in people living with PSP. It is validated 45-item questionnaire and visual analog scale that is comprised of 2 subscales: physical health state (22 items), which covers mobility, dysarthria, dysphagia, visual disturbances, self-care, and activities of daily living, and mental health state (23 items), which covers emotional, cognitive and social functioning. Items are given a 6-reponse option format (No Problem, Slight Problem, Moderate Problem, Marked Problem, Extreme Problem and Not Applicable). The subscale results are derived by summing the respective items for that subscale and transforming the scores into a range of 0 to 100, the higher the scores indicating a greater impact of the disease on the aspect measured. The PSP-QoL also comprises of a Life Satisfaction rating gauge, which is a visual analog scale with a range of 0 (worst) to 100 (best).

    Measured: Baseline, Week 52

  6. Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48

    The SEADL scale is a means of assessing a person's ability to perform daily activities in terms of speed and independence, with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). A negative change from baseline indicates worsening.

    Measured: Baseline, Week 48

  7. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52

    The Clinical Global Impression of Severity (CGI-S) Rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that that requires the clinician to rate the severity of the patient's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Measured: Baseline, Week 52

  8. Change From Baseline in Phonemic Fluency Test Score at Week 48

    Phonemic fluency is a sensitive test for assessing frontal lobe dysfunction. Participants are given a letter of the alphabet and asked to name as many words as they can that start with that letter in 1 minute. The score for each trial is auto-calculated as follows: Trial 1: Total number of correct responses for the first letter (range 0 to 40); Trial 2: Total number of correct responses for the second letter (range 0 to 40). The total score from the two trials will be used for analysis (range 0 to 80). More number of words correlates to better phonemic fluency. A negative change from baseline indicates worsening.

    Measured: Baseline, Week 48

  9. Change From Baseline in Letter-Number Sequencing Test at Week 48

    Letter number is a test of working memory which involves ordering a series of up to 8 letters and numbers in which the numbers are repeated back first in order starting with the lowest number, then followed by the letters in alphabetical order. LNS consists of 10 items and each item has 3 trials rated as Incorrect (0) or Correct (1). The LNS total raw score (range 0 to 30) is auto-calculated by summing the 10 individual item scores (range 0 to 3 for each item). Higher number of correct items correlated to better performance and a negative change from baseline indicates worsening.

    Measured: Baseline, Week 48

  10. Change From Baseline in Color Trails at Week 48

    The Color Trails test is a language free version of the Trail Making Test and was developed to allow for broader cross cultural assessment. For Part 1 (color trails test 1), the respondent uses a pencil to rapidly connect circles numbered 1-25 in sequence. For Part 2 (color trails test 2), the respondent rapidly connects number circles in sequence, but alternates between pink and yellow background. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors. Less time indicates better performance. A positive change from baseline indicates worsening.

    Measured: Baseline, Week 48

  11. Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48

    The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0-30, with higher score being better performance. A negative change from baseline indicates worsening.

    Measured: Baseline, Week 48

  12. Number of Participants With Treatment Emergent Antibodies (Anti-BIIB092) Positive Results in Serum

    Measured: Up to Week 48

  13. Change From Baseline of Brain Volumes as Determined by MRI at Week 52

    A 3 dimension (3D) T1-weighted MRI was performed to estimate brain volumes (e.g., ventricles, whole brain, midbrain, pons, superior cerebellar peduncle, third ventricle, and frontal lobes).

    Measured: Baseline, Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Mar 2017
  2. Study start1 Jun 2017
  3. Primary completion6 Sep 2019
  4. Study completion7 Feb 2020

Why it stopped: 251PP301(PASSPORT) primary endpoint was not met;Biogen decision to close the study early. There were no safety concerns with the PASSPORT study.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
490 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03068468
Sponsor's protocol ID
251PP301
Other IDs
2016-002554-21, CN002-012, 2016
Acronym
PASSPORT
Status last verified
Nov 2020
First submitted
27 Feb 2017
Last updated
21 Dec 2020
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Quattrone A, Franzmeier N, Huppertz HJ, Klietz M, Roemer SN, Boxer AL, Levin J, Hoglinger GU; AL-108-231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE-PSP Group. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials. Mov Disord. 2024 Aug;39(8):1329-1342. doi: 10.1002/mds.29866. Epub 2024 Jun 2.

    PubMed 38825840
  • Jaeger J, Yang L, Li Y, Castrillo-Viguera C, Haeberlein SB, Dam T, O'Gorman J. Development of a cognitive composite for measuring change in progressive supranuclear palsy. Parkinsonism Relat Disord. 2021 Nov;92:94-100. doi: 10.1016/j.parkreldis.2021.10.007. Epub 2021 Oct 12.

    PubMed 34736158
  • Dam T, Boxer AL, Golbe LI, Hoglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12.

    PubMed 34385707

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BIIB092 in people with Supranuclear Palsy, Progressive, run by Biogen at 86 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 86 sites in United States, Germany, France, Japan, United Kingdom and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Dec 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52 (time frame: Baseline, Week 52). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03068468, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in